WELLINGTON MANAGEMENT GROUP LLP 13D and 13G filings for Syndax Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 10:52 am Sale | 2024-09-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX | WELLINGTON MANAGEMENT GROUP LLP | 4,985,976 5.860% | -2,599,245 (-34.27%) | Filing |
| 2024-02-08 10:18 am Sale | 2023-12-29 | 13G | Syndax Pharmaceuticals, Inc. SNDX | WELLINGTON MANAGEMENT GROUP LLP | 7,585,221 8.940% | -398,221 (-4.99%) | Filing |
| 2023-01-10 09:23 am Purchase | 2022-12-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX | WELLINGTON MANAGEMENT GROUP LLP | 7,983,442 11.720% | 6,384,676 (+399.35%) | Filing |
| 2022-02-04 09:24 am Sale | 2021-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | WELLINGTON MANAGEMENT GROUP LLP | 1,598,766 3.040% | -1,016,677 (-38.87%) | Filing |
| 2021-02-04 10:27 am Purchase | 2020-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | WELLINGTON MANAGEMENT GROUP LLP | 2,615,443 5.540% | 441,220 (+20.29%) | Filing |
| 2020-12-10 08:12 am Sale | 2020-11-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX | WELLINGTON MANAGEMENT GROUP LLP | 2,174,223 5.320% | -869,467 (-28.57%) | Filing |